Home › Trial NCT06151691
Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach
- Trial IDNCT06151691
- StatusUnknown
- PhaseN/A
- Study typeObservational
- SponsorFudan University
- Enrollment51
- Start date2023-12-01
- ConditionsPancreatic Ductal Adenocarcinoma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.